# Clinical Trials Data EGFR - Document 60

# Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT01665417

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT); Patients must have previously untreated locally advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).\n\nExclusion Criteria:\n\n\* Prior chemotherapy Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR Patients must not be receiving any other investigational agents Any evidence of interstitial lung disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with an EGFR activating mutation (specifically exon 19 deletion or L858R) would be eligible for this trial, \*provided\* they also meet the other inclusion criteria (confirmed adenocarcinoma, measurable disease, previously untreated locally advanced or metastatic NSCLC) and \*do not\* meet any of the exclusion criteria (prior chemotherapy, prior treatment with EGFR-targeting drugs, other investigational agents, evidence of interstitial lung disease). The trial specifically requires documentation of an EGFR activating mutation.